These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12823782)

  • 21. FDA panel recommends two new cancer drugs for approval.
    Finkelstein JB
    J Natl Cancer Inst; 2001 Feb; 93(3):175-6. PubMed ID: 11158184
    [No Abstract]   [Full Text] [Related]  

  • 22. Alemtuzumab in chronic lymphocytic leukemia.
    James DF; Kipps TJ
    Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DAT-negative hemolytic anemia in a chronic lymphocytic leukemia patient treated with alemtuzumab.
    d'Arena G; de Filippi R; Pinto A
    Leuk Lymphoma; 2007 Mar; 48(3):625-7. PubMed ID: 17454610
    [No Abstract]   [Full Text] [Related]  

  • 24. Alemtuzumab-resistant Sézary syndrome responding to zanolimumab.
    Alexandroff AB; Shpadaruk V; Bamford WM; Kennedy DB; Burd R; Dyer MJ
    Br J Haematol; 2011 Aug; 154(3):419-21. PubMed ID: 21480857
    [No Abstract]   [Full Text] [Related]  

  • 25. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study.
    Kim SJ; Kim K; Kim BS; Suh C; Huh J; Ko YH; Kim WS
    Ann Oncol; 2009 Feb; 20(2):390-2. PubMed ID: 19211502
    [No Abstract]   [Full Text] [Related]  

  • 26. Alemtuzumab treatment for hemophagocytic lymphohistiocytosis.
    Machaczka M; Vaktnäs J; Chiang SC; Bryceson YT
    Nat Rev Clin Oncol; 2010 Oct; 7(10):. PubMed ID: 21080519
    [No Abstract]   [Full Text] [Related]  

  • 27. Alemtuzumab: what is the secret to safe therapy?
    Elter T; Hallek M; Montillo M
    Clin Adv Hematol Oncol; 2011 May; 9(5):364-73. PubMed ID: 21685865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Ferrajoli A; Wierda WG; LaPushin R; O'Brien SM; Faderl S; Browning ML; Keating MJ
    Eur J Haematol; 2008 Apr; 80(4):296-8. PubMed ID: 18182081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is alemtuzumab really the single active agent for treatment of chronic lymphocytic leukemia?
    Oberoi SS; Abou Jawde RM
    J Clin Oncol; 2008 Dec; 26(35):5827-8; author reply 5828-9. PubMed ID: 19001335
    [No Abstract]   [Full Text] [Related]  

  • 30. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
    Moreton P; Hillmen P
    Semin Oncol; 2003 Aug; 30(4):493-501. PubMed ID: 12939718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders.
    Gibbs SD; Westerman DA; McCormack C; Seymour JF; Miles Prince H
    Br J Haematol; 2005 Jul; 130(1):87-91. PubMed ID: 15982349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab.
    Laurenti L; Tarnani M; Innocenti I; Savino G; Battendieri R; Larocca LM; Chiusolo P; Sorà F; Sica S; Efremov D; Leone G
    J Clin Oncol; 2008 Nov; 26(32):5299-301. PubMed ID: 18854557
    [No Abstract]   [Full Text] [Related]  

  • 33. Alemtuzumab.
    Ravandi F; O'Brien S
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
    Grey M
    Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
    [No Abstract]   [Full Text] [Related]  

  • 35. Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy.
    Bolli N; Di Ianni M; Simonetti S; Cerroni L; Liso A; Falini B; Tabilio A
    Lancet Oncol; 2004 Jan; 5(1):64-5. PubMed ID: 14700612
    [No Abstract]   [Full Text] [Related]  

  • 36. [Therapeutic monoclonal antibodies].
    Geissler M; Blum HE
    Dtsch Med Wochenschr; 2000 Dec; 125(49):1501-4. PubMed ID: 11149212
    [No Abstract]   [Full Text] [Related]  

  • 37. Disseminated molluscum contagiosum in a patient with chronic lymphocytic leukaemia after alemtuzumab.
    Pitini V; Arrigo C; Barresi G
    Br J Haematol; 2003 Nov; 123(4):565. PubMed ID: 14616955
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.
    Osterborg A; Mellstedt H; Keating M
    Med Oncol; 2002; 19 Suppl():S21-6. PubMed ID: 12180488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alemtuzumab for refractory celiac disease.
    Verbeek WH; Mulder CJ; Zweegman S
    N Engl J Med; 2006 Sep; 355(13):1396-7; author reply 1397. PubMed ID: 17005966
    [No Abstract]   [Full Text] [Related]  

  • 40. Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab.
    Chu D; Stevens M; Gladstone DE
    Rheumatol Int; 2007 Oct; 27(12):1173-5. PubMed ID: 17443327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.